

COSTING GUIDELINES FOR TUBERCULOSIS INTERVENTIONS

LUCY CUNNAMA
INÉS GARCIA BAENA
GABRIELA GOMEZ
YOKO LAURENCE
CAROL LEVIN
MARIANA SIAPKA
SEDONA SWEENEY
ANNA VASSALL
EDINA SINANOVIC

COSTING GUIDELINES FOR TUBERCULOSIS INTERVENTIONS

**LUCY CUNNAMA
INÉS GARCIA BAENA
GABRIELA GOMEZ
YOKO LAURENCE
CAROL LEVIN
MARIANA SIAPKA
SEDONA SWEENEY
ANNA VASSALL
EDINA SINANOVIC**

Costing guidelines for tuberculosis interventions/ Lucy Cunnama, Inés Garcia Baena, Yoko Laurence, Sedona Sweeney, Anna Vassall, Edina Sinanovic et al.

ISBN 978-92-4-000009-4

© **World Health Organization 2019**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Cunnama L, Garcia Baena I, Laurence Y, Sweeney S, Vassall A, Sinanovic E et al. Costing guidelines for tuberculosis interventions. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Cover designed by Irwin Law

Copy editing by Galbraith-Emami Associates

Designed by minimum graphics

CONTENTS

Acknowledgements	v
Abbreviations	vii
SECTION A. Introduction	1
Background	1
Aim of the guidelines	2
SECTION B. Defining TB interventions	4
Standardized unit costs for TB interventions	4
SECTION C. Study objectives and set-up	8
Initial conceptualization and defining the study team	10
Study protocol formation and submission of protocol for ethical approval	13
SECTION D. Designing data collection	18
Understanding the production process	18
Costing approaches	21
The Standardized Value TB Costing Tool Suite	28
SECTION E. Data analysis, presenting results and dissemination of cost data	31
SECTION F. Appendices	33
Appendix 1. Basic concepts and terms in costing	33
Appendix 2. Specific TB interventions	37
Appendix 3. Standardized unit costs for TB interventions	43
Appendix 4. Principles and methods reporting checklist	49
Appendix 5. Amortization table	53
Appendix 6. Protocol outline	54
Appendix 7. Examples of queries and comments from ethics committees	55
Appendix 8. Value TB Costing Tool Suite	57
Appendix 9. Non-exhaustive list of unit costs per patient per output, top-down and bottom-up generated by the Data Entry Tool	105
Appendix 10. Terms of reference for the study team	106
Appendix 11. Three case studies	114
Appendix 12. Informed consent templates	117
References	123

List of figures and tables

Figure 1. Standard unit costs	5
Figure 2. Example of activities for national costing study (example of Value TB)	8
Figure 3. Example of timeline for national costing study (example of Value TB)	16
Figure 4. Example of a process flow diagram for smear microscopy in a laboratory	19
Figure 5. Capital and recurrent inputs	20
Figure 6. Estimating efficiency	22
Figure 7. Top-down allocation of costs within a laboratory	24
Figure 8. Post data collection activities	31
Figure 9. Intervention flow chart	37
Figure 10a. The Value TB Costing Tool Suite	57
Figure 10b. The Value TB Costing Tool Suite	82
Figure 11. Shared above service level costs	97
Table 1. Sample of annex 3 from Reference Case [5] for TB treatment	7
Table 2. Costing approaches	25
Table 3. Defining standard costs for each intervention	41

ACKNOWLEDGEMENTS

These guidelines were jointly produced by a core writing team comprising the following people: Lucy Cunnama, Health Economics Unit, University of Cape Town (UCT), Cape Town, South Africa; Inés Garcia Baena, Global TB Programme, World Health Organization (WHO), Geneva, Switzerland; Gabriela Gomez, London School of Hygiene and Tropical Medicine (LSHTM), London, England; Yoko Laurence, LSHTM, London, England; Carol Levin, University of Washington, Seattle, United States of America; Mariana Siapka, LSHTM, London, England; Sedona Sweeney, LSHTM, London, England; Anna Vassall, LSHTM, London, England; and Edina Sinanovic, UCT, Cape Town, South Africa. The writing team forms part of the Global Health Cost Consortium (GHCC), which will disseminate the guidelines alongside WHO.

The core writing team would like to thank the Value TB project research groups in Ethiopia, Georgia, India, Kenya and the Philippines, who were the first users of the guidelines. Their feedback shaped the Value TB Costing Tool Suite, which is the set of costing instruments that accompanies the guidelines.

Special thanks are due to Katherine Floyd for providing inspiration to produce new guidelines on TB costing and for her support to both the GHCC and the Value TB project. Thanks are also due to the TB Modelling and Analysis Consortium (TB MAC) and the WHO Global Taskforce on TB Impact Measurement, for feedback on the reporting formats during two of their joint annual meetings, in September 2017 and September 2019.

Funding for this work was provided by the Bill and Melinda Gates Foundation (grant no. OPP1109722), through the GHCC.

ABBREVIATIONS

3HP	three months of once-weekly isoniazid and rifapentine
6H	isoniazid for six months
ACF	active case finding
ALT	alanine aminotransferase
ART	antiretroviral therapy
AST	aspartate aminotransferase (also known as SGOT)
BCG	Bacille Calmette-Guérin
BMI	body mass index
COPD	chronic obstructive pulmonary disease
CPI	consumer price index
CT	computed tomography
CXR	chest x-ray
DOTS	directly observed therapy, short-course
DR	drug-resistant
DS	drug-susceptible
DS-TB	drug sensitive tuberculosis
DST	drug susceptibility testing
ECG	electrocardiography
EPTB	extra-pulmonary tuberculosis
FLD	first-line drugs
FTE	full-time equivalent
GFATM	Global Fund to Fight AIDS, Tuberculosis and Malaria
GHCC	Global Health Cost Consortium
H	isoniazid
HCW	health care worker
HEU UCT	Health Economics Unit, University of Cape Town
HMIS	health management information system
HR	human resources
ICF	intensified case finding
IEC	information, education and communication
IGRA	interferon-gamma release assay
INH	isoniazid
IPD	inpatient department
IPT	isoniazid preventive therapy
KEMRI	Kenya Medical Research Institute
KEMRI-WT	Kenya Medical Research Institute Wellcome Trust
LAMP	loop-mediated isothermal amplification
LED	light-emitting diode
LF-LAM	lateral flow urine lipoarabinomannan assay

LJ	Lowenstein-Jensen
LPA	line probe assay
LSHTM	London School of Hygiene and Tropical Medicine
LTBI	latent tuberculosis infection
M-health	mobile-health
MCH	maternal and child health
MDR	multidrug-resistant (resistant to both rifampicin and isoniazid)
MDR-TB	multidrug resistant tuberculosis
MGIT	mycobacteria Growth Indicator Tube
NCDs	noncommunicable diseases
NGOs	non-governmental organizations
NTLP-P	National Tuberculosis, Leprosy and Lung Disease Program
NTP	National Tuberculosis Programme
OPD	outpatient department
PCF	passive case finding
PCR-DNA	polymerase chain reaction – deoxyribonucleic acid
PI	principal investigator
PMT	payment function
PPD	purified protein derivative
PTB	pulmonary tuberculosis
R	rifampicin
RBC	red blood cell
RBS	random blood sugar (also known as random blood glucose)
S	streptomycin
SGOT	serum glutamic-oxaloacetic transaminase (also known as AST)
SGPT	serum glutamic-pyruvic transaminase (also known as ALT)
SLD	second-line drugs
TB	tuberculosis
TST	tuberculin skin test (also known as PPD Mantoux test)
UHC	Universal Health Coverage
UNICEF	United Nations Children's Fund
USD	United States dollars
UV	ultraviolet
WBC	white blood cell

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24927

